Stereotactic Body Radiation Therapy for Prostate Adenocarcinoma
This trial is testing a way to predict which prostate cancer patients will experience long-term genitourinary toxicity after radiation therapy, so that patients and doctors can make more informed decisions about treatment.
- Prostate Adenocarcinoma
- Stage I Prostate Cancer
- Stage II Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer
1 Primary · 9 Secondary · Reporting Duration: Up to 5 years
Side Effects for
1 Treatment Group
Treatment (radiotherapy, genomic DNA testing)
1 of 1
198 Total Participants · 1 Treatment Group
Primary Treatment: Stereotactic Body Radiation Therapy · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · Male Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are in the clinical trial at its peak capacity?
"Affirmative. Clinical trial records hosted on clinicaltrials.gov confirm that this medical research, which was first published on November 10th 2020, is still open for applicants. The study aims to enlist 200 participants from a single centre." - Anonymous Online Contributor
Are there still vacancies available for participation in this experiment?
"According to the clinicaltrials.gov, this medical trial is currently recruiting participants with initiation of recruitment beginning in November 2020 and most recent update taking place on December 1st 2022." - Anonymous Online Contributor